Overview

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Status:
Active, not recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborators:

Amgen
Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab
Panitumumab